FDA Advisory Panel is Split on Naloxone Dose

October 27th, 2016

As a follow-up to the October 13 post, this report provides more details and further discussion on the FDA Advisory Board’s split decision on whether the injectable 0.4-mg dose of naloxone should remain the current standard by which products containing the opioid overdose reversal drug should be measured.

Learn More

Posted in Content

A Project of the Governor's Institute on Alcohol & Substance Abuse and the North Carolina Society of Addiction Medicine.
Funded wholly or in part by the federal Substance Abuse Prevention and Treatment Block Grant Fund (CFDA #93.959) as a project of the NC Division of Mental Health, Developmental Disabilities & Substance Abuse Services.